share_log
Reuters ·  Dec 3 20:06
Spur Therapeutics: Initiating Investigational New Drug -Enabling Studies to Support Advancement of Spr301 Into a Phase 1/2 Clinical Trial in 2026
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment